

Indian Equities

Company Update

Change in Estimates ☑ Target ☑ Reco □

11 February 2025

Escorts Kubota

Better performance expected ahead; retaining a Buy

Escorts' Q3 PBT (incl. discontinued operations) grew 7% y/y to Rs4.2bn, below ARe of Rs4.4bn mainly due to less-than-expected agri machinery margins. We are enthused about the company as we believe FY25 would bring a ramp-up in its Vision 2028 execution and a turnaround in tractors. Its merger with Kubota, strong tractor cycle, new products & platforms, and recovery in exports will be positive for the company. Key Vision 2028 strategies: new platforms for domestic/exports, component/R&D services exports, operating captive finance and ramping up plans for other segments. We expect healthy (incl. JV, Railways divestment), 14%/22% revenue/EBIT CAGRs over FY25-27. The stock trades at 31x/24x FY26e/FY27e core P/E. We retain a Buy rating, with a lower Rs3,900 TP (earlier Rs4,300), 30x FY27e core EPS and Rs603/sh cash.

PBT below estimate. Revenue (incl. discontinued operations) grew 8% y/y to Rs31.4bn, broadly in line with our estimated Rs31.3bn. PBT grew 7% y/y to Rs4.2bn, below ARe of Rs4.4bn mainly due to less-than-expected agri machinery margins. Overall, PAT grew 9% y/y to Rs3.2bn, below our estimated Rs3.4bn on lower-than-expected operating profit.

Segment-wise. Agri revenue grew 9% y/y, 28% q/q to Rs24.2bn, led by higher, 4% y/y, volumes and increased, 5% y/y, realizations. The EBIT margin contracted 160bps y/y but rose 130bps q/q to 10.4%. Construction equipment revenue grew 4% y/y to Rs5.2bn; volumes fell 1% y/y, while realizations grew 5% y/y. The EBIT margin expanded 290ps y/y, 170bps q/q, to 11%.

Valuation. We expect healthy 14%/19% revenue/PAT CAGRs over FY25-27. We cut our FY26e/27e EPS ~10-11%, mainly due to lower tractor and construction equipment volumes. We retain a Buy rating with a lower TP of Rs3,900 (earlier Rs4,300; 30x FY27e), 30x FY27e core EPS and Rs603/sh cash. **Key risks:** Slower-than-expected execution of new opportunities, lower industry volume growth and adverse commodity prices.


Key financials (YE Mar) - P	FY23	FY24	FY25e	FY26e	FY27e	
Sales (Rs m)	83,450	1,06,811	1,01,412	1,15,854	1,31,770	
Net profit (Rs m)	7,041	10,816	11,098	12,587	15,642	
EPS (Rs)	53.4	96.7	96.7 99.2 112.5		139.8	
P/E (x)	61.9	1.9 34.2 33.3		29.4	23.6	
EV / EBITDA (x)	48.7	23.5	24.1	19.8	16.0	
P/BV (x)	5.2	3.9	3.9 3.1		2.7	
RoE (%)	8.6	12.1	10.5	10.3	12.0	
RoCE (%)	8.3	12.1	9.3			
Dividend yield (%)	0.2	0.5 1.2	0.2 0.5	5 1.2		1.7
Net debt / equity (x)	-0.7	-0.6	-0.7	-0.7	-0.6	

Rating: **Buy**Target Price (12-mth): Rs.3,900
Share Price: Rs.3,303

Key data	ESCORTS IN / ESCO.BO
52-week high / low	Rs4422 / 2671
Sensex / Nifty	77312 / 23382
3-m average volume	\$8m
Market cap	Rs370bn / \$4224.5m
Shares outstanding	112m
Shares outstanding	112

Shareholding pattern (%)	Dec'24	Sep'24	Jun'24
Promoters	68.0	68.0	67.7
- of which, Pledged	-	-	-
Free float	32.0	32.0	32.4
- Foreign institutions	5.9	6.3	6.4
- Domestic institutions	10.2	10.2	10.4
- Public	15.9	15.4	15.6

Estimates revision (%)	FY25e	FY26e	FY27e
Sales	-11.7	-7.6	-11.1
EBITDA	-16.3	-10.6	-11.0
EPS	-14.4	-10.6	-10.4



Source: Bloomberg

Mumuksh Mandlesha Research Analyst

> Shagun Beria Research Associate

Dishant Jain Research Associate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Anand Rathi Research India Equities

Reported PAT (incl.

discontinued ops)

Quick Glance – Financials and Valuations (Standalone)

Fig 1 – Income statement (Rs m)										
Year-end: Mar	FY23	FY24	FY25e	FY26e	FY27e					
Net revenues	83,450	1,06,811	1,01,412	1,15,854	1,31,770					
Growth (%)	16	28	-5	14	14					
Raw material	60,669.4	75,287.8	71,874.9	81,581.6	91,847.5					
Employee & other expenses	14,976	18,320	17,747	20,043	22,269					
EBITDA	7,804	13,203	11,790	14,230	17,653					
EBITDA margins (%)	9.4	12.4	11.6	12.3	13.4					
- Depreciation	1,484	2,328	2,436	2,673	2,935					
Other income	2,806	3,926	4,240	4,876	5,608					
Interest expenses	103	393	256	192	144					
PBT	9,995	14,409	-2,661	16,241	20,183					
Effective tax rates (%)	22	25	17	23	23					
+ Associates / (Minorities)										
Adj. income (cont. ops)	7,041	10,816	11,098	12,587	15,642					
Extraordinary items	972	-	-16,000	-	-					
Net income (cont. ops)	6,070	10,816	27,098	12,587	15,642					
WANS	132	112	112	112	112					
FDEPS (Rs)	53	97	99	113	140					
Growth (%)	-8	81	3	13	24					

6,070 10,816

28,366

12,587

15,642

Fig 2 – Balance sheet (Rs m)								
Year-end: Mar	FY23	FY24	FY25e	FY26e	FY27e			
Share capital	1,319	1,119	1,119	1,119	1,119			
Net worth	84,348	94,165	1,18,092	1,25,644	1,35,029			
Debt (including Pref)	-	3,634	520	520	520			
Minority interest	-	-	-	-				
DTL / (Assets)	651	987	974	957	937			
Capital employed	84,999	98,785	1,19,585	1,27,121	1,36,486			
Net tangible assets	18,085	21,637	25,302	30,329	38,995			
Investments (strategic)	33,154	29,824	29,824	29,824	29,824			
Investments (financial)	17,949	20,902	40,902	45,902	50,902			
Current assets (excl. cash)	28,071	38,223	34,100	37,979	42,089			
Cash	4,685	11,915	15,222	11,946	7,375			
Current liabilities	18,082	25,316	26,264	29,658	33,899			
Working capital	9,989	12,906	7,836	8,321	8,190			
Capital deployed	84,999	98,785	1,19,585	1,27,121	1,36,486			

14,409 2,721 17,129 3,763 3,076 10,291 6,344 3,947	30,607 2,692 33,298 -2,645 2,254 33,690 5,000	16,241 2,865 19,106 1,081 3,670 14,355 8,000	23,261 1,092 4,561 17,608
17,129 3,763 3,076 10,291 6,344	33,298 -2,645 2,254 33,690 5,000	19,106 1,081 3,670 14,355 8,000	4,561 17,608
3,763 3,076 10,291 6,344	-2,645 2,254 33,690 5,000	1,081 3,670 14,355 8,000	1,092 4,561 17,608
3,076 10,291 6,344	2,254 33,690 5,000	3,670 14,355 8,000	17,608
10,291 6,344	33,690 5,000	14,355 8,000	
6,344	5,000	8,000	17,608 12,000
			12,000
3 947	00.000		
0,041	28,690	6,355	5,608
924	2,014	4,439	5,035
-	-	-	-
3,634	-3,114	-	-
-378	20,000	5,000	5,000
(195)	256	192	144
7,230	3,307	-3,276	-4,571
	-378 (195) 7,230	-378 20,000 (195) 256 7,230 3,307	-378 20,000 5,000 (195) 256 192

Year-end: Mar	FY23	FY24	FY25e	FY26e	FY27e
P/E (x)	61.9	34.2	33.3	29.4	23.6
EV / EBITDA (x)	48.7	23.5	24.1	19.8	16.0
EV / Sales (x)	4.6	2.9	2.8	2.4	2.1
P/B (x)	5.2	3.9	3.1	2.9	2.7
RoE (%)	8.6	12.1	10.5	10.3	12.0
RoCE (%) - after tax	8.3	12.1	9.3	10.0	11.6
RoIC (%) - after tax	18.5	28.1	23.1	26.5	27.5
DPS (Rs)	7.0	18.0	39.7	45.0	55.9
Dividend yield (%)	0.2	0.5	1.2	1.4	1.7
Dividend payout (%)	13.1	18.6	40.0	40.0	40.0
Net debt / equity (x)	-0.7	-0.6	-0.7	-0.7	-0.6
Receivables (days)	53	50	50	50	50
Inventory (days)	51	57	54	51	48
Payables (days)	54	56	55	54	53
CFO:PAT %	34	95	304	114	113

Fig 5 - Price movement





Fig 6 - Revenue, by segment (Q3 FY25)



Source: Company

Result highlights

(Rs m)	Q3 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Y/Y (%)	Q/Q (%)	YTD FY25
Revenue	27,064	25,563	22,649	29,354	8.5	29.6	77,567
Expenditure	23,826	22,394	20,321	26,002	9.1	28.0	68,717
as % of sales	88.0	87.6	89.7	88.6			88.6
RM cost	19,617	18,092	15,766	21,444	9.3	36.0	55,302
as % of sales	72.5	70.8	69.6	73.1			71.3
Employee cost	1,742	1,729	1,861	1,983	13.8	6.5	5,573
as % of sales	6.4	6.8	8.2	6.8			7.2
Other expenditure	2,467	2,573	2,694	2,575	4.4	(4.4)	7,841
as % of sales	9.1	10.1	11.9	8.8			10.1
EBITDA	3,238	3,169	2,328	3,353	3.5	44.0	8,850
EBITDA margin (%)	12.0	12.4	10.3	11.4			11.4
Depreciation	565	590	610	612	8.4	0.5	1,812
EBIT	2,673	2,579	1,718	2,740	2.5	59.5	7,038
Other income	1,004	1,024	1,152	1,092	8.8	(5.2)	3,268
Interest	104	101	92	31	(70.6)	(66.8)	223
PBT	3,573	3,502	2,779	3,802	6.4	36.8	10,082
Total tax	876	840	-248	897	2.5	(461.6)	1,489
Net profit from continuing operations	2,698	2,662	3,027	2,905	7.7	(4.0)	8,593
Profit before tax from discontinued operations	376	501	322	438			760
Tax expense of discontinued operations	96	127	81	111			192
Net Profit (Adjusted) including discontinued ops	2,979	3,035	3,267	3,232	8.5	(1.1)	9,161
Extraordinary items Loss/(Gain)	0	0	0	0			0
Adjusted EPS (Rs)	24.4	23.8	27.1	26.0	6.3	(4.0)	76.8

Margins (%)					(bps)	(bps)	
Gross	27.5	29.2	30.4	26.9	(57)	(344)	28.7
EBIDTA	12.0	12.4	10.3	11.4	(54)	114	11.4
EBIT	9.9	10.1	7.6	9.3	(54)	175	9.1
EBT	13.2	13.7	12.3	13.0	(25)	68	13.0
PAT	10.0	10.4	13.4	9.9	(7)	(347)	11.1
Effective Tax rate	24.5	24.0	(8.9)	23.6	(90)	3,253	14.8
Source: Company. Includes JV financials							

Earnings Call Takeaways

- Tractors underperformed in the domestic market in Q3 FY25 due to slower growth in north/central regions (+2.5%) and dealer inventory corrections (4 weeks from 35-37 days in Q2). Inventory correction was done to improve dealers' profitability (particularly Kubota and new management's restructuring efforts). Now, almost through with inventory correction. Domestic industry to grow by 6-7% in FY25, 14-15% in Q4 FY25; good growth is expected in Q1 FY26. Exports growth in recent times was mainly driven by higher volumes through Kubota's network in Europe.
- Q3 non-tractor (agri machinery, engines, spare parts) sales contributed 21% of revenue (vs. 19% in Q3 FY24 and 18% in Q2 FY25). The share of spare parts/engine was 8%, while the rest came from farm implements. Component exports to ramp-up from FY26 after supplier quality checks are completed.
- Captive finance started for selected states and dealerships. A notable ramp-up is expected by H2 FY26.
- Escorts Kubota's number of dealers was ~1,540 as of Dec'24 vs. ~1,500 as of Sep'24.
- New products. The PROMAXX Series (Farmtrac brand) was launched in 30-50 HP category to target markets in west and central India (Gujarat, Maharashtra, Chhattisgarh, Odisha and MP), to improve market share in white spaces. In construction equipment, new entry-level Hydra Cranes & BLX-75 Backhoe Loader (E Kubota brand) were launched.
- Construction equipment. The company expects flattish volume growth for FY26 due to price hikes. Certain products moved from BS3 to BS5 (~10% hike) and BS4 to BS5 (~5% hike). Initially, there was partial pass-through of higher cost; however, recovery is expected over time.
- Q3 gross margin came lower due to the inventory change impact, higher input prices and discounts (due to festivals).
- Q3 FY25 Railways PBIT was Rs440m.
- The Board approved sale of 33,000+ square yards of land adjacent to the Railway Equipment Division to Sona Comstar for Rs1.1bn. The company will relocate the spare parts division before finalizing the sale.
- The greenfield plant planned in Uttar Pradesh has been delayed due to land acquisition issues.

Valuations

We are upbeat regarding the company as we believe FY25 would bring a ramp-up in its Vision 2028 execution and a turnaround in tractors. The company's merger with Kubota, strong tractor cycle, new products and platforms, and exports recovery would be positive.

FY25, a year of execution with merger of JVs. 1) Launches of products developed for domestic/exports. 2) Exports of components and R&D services (inaugurated a large warehouse of 58,000 sq.ft.). 3) Operating captive finance to support the domestic market share with earmarked capital of Rs7bn. 4) Ramping up plans for other key segments—construction equipment, implements, engines and spare parts—where the company has huge aspirations.

Turnaround in tractor industry. Turnaround in tractors began with a double-digit festival period growth. Double-digit growth is expected in H2 and over 7% growth in FY25.

New opportunities to add >5% growth. Further, opportunities such as domestic market-share gains, exports, components, R&D, implements and engines would drive >5% growth over the normal 8-10%. We expect healthy (incl. JV, Railways divestment), 14%/22% revenue/EBIT CAGRs over FY25-27.

Valuation. We recommend a Buy with a TP of Rs3,900, 30x FY27e core EPS and Rs603/sh cash (0.8x book).

78,974			FY27e	CAGR % FY25-27e
,	83,800	94,946	1,07,085	13
	6	13	13	
18,182	17,460	19,056	21,983	12
	-4	9	15	
9,504				
		1,500	2,250	
			50	
		200	300	
			50	
152	152	152	152	
1,06,811	1,01,412	1,15,854	1,31,770	7
	-5	14	14	
	9,504	18,182 17,460 -4 9,504 152 152 1,06,811 1,01,412	18,182 17,460 19,056 -4 9 9,504 1,500 200 152 152 152 1,06,811 1,01,412 1,15,854	18,182 17,460 19,056 21,983 -4 9 15 9,504 1,500 2,250 50 200 300 50 50 152 152 152 152 1,06,811 1,01,412 1,15,854 1,31,770

Fig 9 – Change in estimates									
_	Old		Revised			Change (%)			
(Rs m)	FY25e	FY26e	FY27e	FY25e	FY26e	FY27e	FY25	FY26	FY27
Revenue	1,14,786	1,25,371	1,48,259	1,01,412	1,15,854	1,31,770	-11.7	-7.6	-11.1
EBITDA	14,089	15,926	19,830	11,790	14,230	17,653	-16.3	-10.6	-11.0
% of revenue	12.3	12.7	13.4	11.6	12.3	13.4			
Adj. PAT	12,962	14,079	17,456	11,098	12,587	15,642	-14.4	-10.6	-10.4
EPS (Rs)	115.9	125.8	156.0	99.2	112.5	139.8	-14.4	-10.6	-10.4
Source: Anand Rathi Resear	ch								

Downside risks


- Slower-than-expected execution of new opportunities.
- Lower industry volume growth.
- Adverse commodity prices.

Appendix

Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies Rating and Target Price History (as of 10 February 2025)



Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps, Mid Caps & Small Caps as described in the Ratings Table below:

Ratings Guide (12 months)					
. ,	Buy	Hold	Sell		
Large Caps (Top 100 companies)	>15%	0-15%	<0%		
Mid Caps (101st-250th company)	>20%	0-20%	<0%		
Small Caps (251st company onwards)	>25%	0-25%	<0%		

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd (BSE), National Stock Exchange of India Ltd. (NSEIL), Metropolitan Stock Exchange of India Ltd. (MSE), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. (CDSL), ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report? ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No No
ARSSELTIES ASSOciates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent of more securities of the subject company	INO
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No
ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	No

NOTICE TO US INVESTORS:

This research report is the product of Anand Rathi Share and Stock Brokers Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated person(s) of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances, and trading securities held by a research analyst account.

Research reports are intended for distribution only to Major U.S. Institutional Investors as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act of 1934 (the Exchange Act) and interpretations thereof by the U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this research report is not a Major U.S. Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated, and/or transmitted onward to any U.S. person which is not a Major U.S. Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major U.S. Institutional Investors, Anand Rathi Share and Stock Brokers Limited has entered into a Strategic Partnership and chaperoning agreement with a U.S. registered broker-dealer: BancTrust Securities USA. Transactions in securities discussed in this research report should be affected through BancTrust Securities USA.

- 1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
- 2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
- 5. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

© 2025. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks or ser

As of the publication of this report, ARSSBL does not make a market in the subject securities.

Additional information on recommended securities/instruments is available on request.

Compliance officer-Deepak Kedia, email id - deepakkedia@rathi.com, Contact no. +91 22 6281 7000

Grievance officer-Madhu Jain-email id- grievance@rathi.com, Contact no. +91 22 6281 7191

ARSSBL registered address: Express Zone, A Wing, 9th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.

Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.